Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on February 18, 2020. The filing primarily reports on the Company's financial results for the fourth quarter and full year ended December 31, 2019, and announces a significant debt financing event.
Key Financial Metrics and Debt Activity
The filing does not contain specific numerical values for revenue, profit, cash flow, or margins within the text of the 8-K itself; these figures are referenced as being contained in the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2).
- Debt Financing: On February 18, 2020, the Company completed a draw-down of an additional tranche of $50 million under its $300 million term loan facility with TPG Specialty Lending, Inc.
- Performance Milestone: The availability of this additional tranche was contingent upon the Company achieving $11 million in net revenues from its IMVEXXY, BIJUVA, and ANNOVERA products for the fourth quarter of 2019.
Material Changes and Events
The primary material change reported is the successful execution of the $50 million debt draw-down, which indicates the Company met its revenue covenants for the fourth quarter of 2019. The filing also serves as a vehicle to disseminate the Company's Q4 and full-year 2019 financial results, which were announced via press release on February 20, 2020.
Guidance, Outlook, and Risks
The Company expressly disclaims any obligation to release publicly any updates or changes in its expectations or forward-looking statements. The filing notes that the financial results and presentation materials are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the liability associated with the forward-looking information contained in the exhibits.
Investor Verification Checklist
- Verify the specific Q4 and full-year 2019 revenue, net income, and cash flow figures in the attached Press Release (Exhibit 99.1).
- Confirm the total outstanding debt balance following the $50 million draw-down against the $300 million facility limit.
- Review the slide presentation (Exhibit 99.2) for management's commentary on the $11 million revenue milestone and future product growth.
- Check for any covenants or interest rate terms associated with the TPG Specialty Lending facility in prior 8-K filings referenced in the text.